Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity

Europe pharmacogenomics market accounted for $1,565.6 million in 2019 and will grow by 7.1% annually over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.
Highlighted with 38 tables and 50 figures, this 125-page report “Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country.

Based on Service, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Genotyping
• SNP Identification
• Diagnostics
• Other Services

Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Polymerase Chain Reaction (PCR)
• Microarray
• Sequencing
• Electrophoresis
• Mass Spectrometry
• Other Technologies

Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Oncology
• Infectious Diseases
• Neurology/Psychiatry
• Cardiovascular
• Pain Management
• Other Applications

Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Hospitals and Clinics
• Pharmaceutical Companies
• Research Institutes

Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
23andMe, Inc.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 31
2.4 Emerging Opportunities and Market Trends 34
2.5 Porter’s Fiver Forces Analysis 38
3 Segmentation of Europe Market by Service 42
3.1 Market Overview by Service 42
3.2 Genotyping 44
3.3 SNP Identification 45
3.4 Diagnostics 46
3.5 Other Services 48
4 Segmentation of Europe Market by Technology 49
4.1 Market Overview by Technology 49
4.2 Polymerase Chain Reaction (PCR) 51
4.3 Microarray 52
4.4 Sequencing 53
4.5 Electrophoresis 54
4.6 Mass Spectrometry 55
4.7 Other Technologies 56
5 Segmentation of Europe Market by Application 57
5.1 Market Overview by Application 57
5.2 Oncology 59
5.3 Infectious Diseases 60
5.4 Neurology/Psychiatry 61
5.5 Cardiovascular 63
5.6 Pain Management 64
5.7 Other Applications 65
6 Segmentation of Europe Market by End User 66
6.1 Market Overview by End User 66
6.2 Hospitals and Clinics 68
6.3 Pharmaceutical Companies 69
6.4 Research Institutes 70
7 European Market 2019-2030 by Country 71
7.1 Overview of European Market 71
7.2 Germany 74
7.3 UK 76
7.4 France 79
7.5 Spain 81
7.6 Italy 83
7.7 Russia 85
7.8 Rest of European Market 87
8 Competitive Landscape 89
8.1 Overview of Key Vendors 89
8.2 New Product Launch, Partnership, Investment, and M&A 93
8.3 Company Profiles 94
23andMe, Inc. 94
Abbott Laboratories 96
Admera Health, LLC 97
Agena Biosciences, Inc. 98
Astra Zeneca PLC 99
Bayer AG 100
Becton, Dickinson and Company 101
Cancer Genetics, Inc. 102
Dynamic DNA Laboratories 103
Empire Genomics LLC 104
F. Hoffmann-La Roche Ltd 105
geneOmbio Technologies Pvt Ltd. 106
Genomic Health, Inc. 107
Illumina, Inc. 108
Laboratory Corporation of America Holdings 109
Myriad Genetics Inc. 110
Oneome LLC 111
Opko Health, Inc. 112
Pathway Genomics Corporation 113
QIAGEN N.V. 114
Quest Diagnostics Incorporated 115
Teva Pharmaceuticals Industries Ltd. 116
Thermo Fisher Scientific Inc. 117
Transgenomic, Inc. 118
9 Investing in Europe Market: Risk Assessment and Management 119
9.1 Risk Evaluation of Europe Market 119
9.2 Critical Success Factors (CSFs) 122
Related Reports and Products 125

Key Players (this may not be a complete list and extra companies can be added upon request):
3M Health Care Limited
Adherium Limited
Amiko Digital Health Limited
AsthmaMD
AstraZeneca plc
Boehringer Ingelheim International GmbH
Capsule Technologies, Inc.
Cohero Health
GlaxoSmithKline plc
Kaia Health Software GmbH
Medical International Research (MIR)
Novartis AG
NuvoAir
Reciprocal Labs (Propeller Health)
Sensiron AG
Tactio Health
Teva Pharmaceuticals Industries Ltd.
Table 1. Snapshot of Europe Pharmacogenomics Market, 2019-2030 19
Table 2. Web-based Resources of Pharmacogenomics 24
Table 3. Main Product Trends and Market Opportunities in Europe Pharmacogenomics Market 34
Table 4. Europe Pharmacogenomics Market by Service, 2019-2030, $ mn 42
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing 47
Table 6. Europe Pharmacogenomics Market by Technology, 2019-2030, $ mn 49
Table 7. Europe Pharmacogenomics Market by Application, 2019-2030, $ mn 57
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry 62
Table 9. Europe Pharmacogenomics Market by End User, 2019-2030, $ mn 66
Table 10. Europe Pharmacogenomics Market by Country, 2019-2030, $ mn 73
Table 11. Germany Pharmacogenomics Market by Service, 2019-2030, $ mn 75
Table 12. Germany Pharmacogenomics Market by Technology, 2019-2030, $ mn 75
Table 13. Germany Pharmacogenomics Market by Application, 2019-2030, $ mn 75
Table 14. UK Pharmacogenomics Market by Service, 2019-2030, $ mn 78
Table 15. UK Pharmacogenomics Market by Technology, 2019-2030, $ mn 78
Table 16. UK Pharmacogenomics Market by Application, 2019-2030, $ mn 78
Table 17. France Pharmacogenomics Market by Service, 2019-2030, $ mn 80
Table 18. France Pharmacogenomics Market by Technology, 2019-2030, $ mn 80
Table 19. France Pharmacogenomics Market by Application, 2019-2030, $ mn 80
Table 20. Spain Pharmacogenomics Market by Service, 2019-2030, $ mn 82
Table 21. Spain Pharmacogenomics Market by Technology, 2019-2030, $ mn 82
Table 22. Spain Pharmacogenomics Market by Application, 2019-2030, $ mn 82
Table 23. Italy Pharmacogenomics Market by Service, 2019-2030, $ mn 84
Table 24. Italy Pharmacogenomics Market by Technology, 2019-2030, $ mn 84
Table 25. Italy Pharmacogenomics Market by Application, 2019-2030, $ mn 84
Table 26. Russia Pharmacogenomics Market by Service, 2019-2030, $ mn 86
Table 27. Russia Pharmacogenomics Market by Technology, 2019-2030, $ mn 86
Table 28. Russia Pharmacogenomics Market by Application, 2019-2030, $ mn 86
Table 29. Pharmacogenomics Market in Rest of Europe by Country, 2019-2030, $ mn 88
Table 30. Product Approvals by Company, January 2016 – April 2019 91
Table 31. Breakdown of Europe Market by Key Vendor, 2019, % 91
Table 32. 23andMe, Inc.: Company Snapshot 94
Table 33. 23andMe, Inc.: Business Segmentation 94
Table 34. 23andMe, Inc.: Product Portfolio 95
Table 35. 23andMe, Inc.: Revenue, 2016-2018, $ mn 95
Table 36. 23andMe, Inc.: Recent Developments 95
Table 37. Risk Evaluation for Investing in Europe Market, 2019-2030 120
Table 38. Critical Success Factors and Key Takeaways 123
Figure 1. Research Method Flow Chart 12
Figure 2. Breakdown of Primary Research 14
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 18
Figure 5. Europe Pharmacogenomics Market, 2019-2030, $ mn 21
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice 23
Figure 7. Impact of COVID-19 on Business 25
Figure 8. Primary Drivers and Impact Factors of Europe Pharmacogenomics Market 27
Figure 9. World Top 10 Causes of Deaths, 2016 30
Figure 10. Primary Restraints and Impact Factors of Europe Pharmacogenomics Market 31
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics 33
Figure 12. Investment Opportunity Analysis 35
Figure 13. Porter’s Fiver Forces Analysis of Europe Pharmacogenomics Market 38
Figure 14. Breakdown of Europe Pharmacogenomics Market by Service, 2019-2030, % of Revenue 42
Figure 15. Europe Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%) 43
Figure 16. Europe Pharmacogenomics Market: Genotyping, 2019-2030, $ mn 44
Figure 17. Europe Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn 45
Figure 18. Europe Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn 46
Figure 19. Europe Pharmacogenomics Market: Other Services, 2019-2030, $ mn 48
Figure 20. Breakdown of Europe Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue 49
Figure 21. Europe Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%) 50
Figure 22. Europe Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn 51
Figure 23. Europe Pharmacogenomics Market: Microarray, 2019-2030, $ mn 52
Figure 24. Europe Pharmacogenomics Market: Sequencing, 2019-2030, $ mn 53
Figure 25. Europe Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn 54
Figure 26. Europe Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn 55
Figure 27. Europe Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn 56
Figure 28. Breakdown of Europe Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue 57
Figure 29. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 58
Figure 30. Europe Pharmacogenomics Market: Oncology, 2019-2030, $ mn 59
Figure 31. Europe Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn 60
Figure 32. Europe Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn 61
Figure 33. Europe Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn 63
Figure 34. Europe Pharmacogenomics Market: Pain Management, 2019-2030, $ mn 64
Figure 35. Europe Pharmacogenomics Market: Other Applications, 2019-2030, $ mn 65
Figure 36. Breakdown of Europe Pharmacogenomics Market by End User, 2019-2030, % of Revenue 66
Figure 37. Europe Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 67
Figure 38. Europe Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn 68
Figure 39. Europe Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn 69
Figure 40. Europe Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn 70
Figure 41. Breakdown of European Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 72
Figure 42. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 73
Figure 43. Pharmacogenomics Market in Germany, 2019-2030, $ mn 74
Figure 44. Pharmacogenomics Market in UK, 2019-2030, $ mn 76
Figure 45. Pharmacogenomics Market in France, 2019-2030, $ mn 79
Figure 46. Pharmacogenomics Market in Spain, 2019-2030, $ mn 81
Figure 47. Pharmacogenomics Market in Italy, 2019-2030, $ mn 83
Figure 48. Pharmacogenomics Market in Russia, 2019-2030, $ mn 85
Figure 49. Pharmacogenomics Market in Rest of Europe, 2019-2030, $ mn 87
Figure 50. Growth Stage of Europe Pharmacogenomics Industry over the Forecast Period 89

Frequently Asked Questions About This Report

Choose License Type

Each market study on Reports Globe will be revised based on COVID-19 impact analysis

How can we help you?

Our salient features

Best Solution

We will help you understand value propositions of various reports across numerous domains and suggest the best possible solution to suffice your research needs.

Customized Research

Our team of analysts and consultants provide assistance for customized research requirements

Max ROI

Guaranteed maximum assistance to help you get your reports at the optimum prices, thereby ensuring maximum returns on investment.

24/7 Support

24X7 availability to help you through the buying process as well as answer any of your doubts.

Our Clients

We've Received Your Request

We Thank You for filling out your requirements. Our sales team will get in touch with you shortly.